
    
      The primary objective of the study is to assess safety and determine the maximum tolerated
      dose of PNK-007 in subjects with relapsed and/or refractory acute myeloid leukemia (AML). The
      secondary objective is to explore the potential clinical efficacy by day 42.

      Treatment plan includes conditioning with cyclophosphamide and fludarabine. PNK-007 will
      administered IV followed by a total of six Recombinant human interleukin 2 (rhIL-2)
      injections to support the NK cells in the body.

      Subjects will be followed for up to 24 months.
    
  